Integrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis
Open Access
- 15 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1699470
Abstract
Background: Psoriasis and metabolic dysfunction–associated fatty liver disease (MAFLD) share pathological features such as chronic inflammation, immune dysregulation, and metabolic disturbance. Increasing evidence suggests biological crosstalk between the two conditions, offering new insights into their shared mechanisms and comanagement. Early-stage MAFLD, characterized by hepatic steatosis without evident inflammation or fibrosis, provides a crucial window for intervention. This study aimed to identify early diagnostic biomarkers linking psoriasis and MAFLD. Methods: Transcriptomic datasets of psoriasis and MAFLD were retrieved from the Gene Expression Omnibus (GEO) database. Weighted gene co-expression network analysis (WGCNA) was used to identify MAFLD-related modules. Shared genes were obtained by intersecting module genes with differentially expressed genes (DEGs) from psoriasis datasets. Machine learning algorithms, including random forest (RF), least absolute shrinkage and selection operator (LASSO), and support vector machine (SVM), were applied to identify hub genes. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, immune infiltration assessment, Spearman correlation, and experimental validation in psoriasis and MAFLD mouse models. Results: Twenty-nine shared genes were identified and found to be enriched in immune and metabolic pathways. Six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—were selected through integrated machine learning analysis and experimental validation. These genes exhibited high diagnostic accuracy and significant correlations with disease severity and immune cell infiltration. Conclusions: This study identified six hub genes—ADRB2, WNT5A, S100A9, FAM110C, S100A12, and TUBB6—as potential cross-disease biomarkers for the comorbidity of psoriasis and MAFLD, and these genes are significantly associated with disease severity. These findings provide new targets for early diagnosis and potential treatment strategies for the comorbidity.Keywords
This publication has 37 references indexed in Scilit:
- Unveiling the molecular mechanisms of Haitang-Xiaoyin Mixture in psoriasis treatment based on bioinformatics, network pharmacology, machine learning, and molecular docking verificationComputational Biology and Chemistry, 2025
- Unveiling the mitophagy puzzle in non-alcoholic fatty liver disease (NAFLD): Six hub genes for early diagnosis and immune modulatory rolesHeliyon, 2024
- Bioinformatic Analysis of the Potential Common Pathogenic Mechanisms for Psoriasis and Metabolic SyndromeInflammation, 2023
- Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatmentJournal of Physiology and Biochemistry, 2023
- Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategiesComputers in Biology and Medicine, 2023
- Association Between Psoriasis and Nonalcoholic Fatty Liver Disease Among Outpatient US AdultsJAMA Dermatology, 2022
- Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patientsClinical Rheumatology, 2019
- FRA1 mediates the activation of keratinocytes: Implications for the development of psoriatic plaquesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Evidence for the involvement of FAM110C protein in cell spreading and migrationCellular Signalling, 2009